Table 3

Association of elevated EBV antibody titer and low antibody ratio of EBNA-1/EBNA-2 with Hodgkin lymphoma risk overall and EBV+ and EBV− Hodgkin lymphoma

AntibodyReferentAll cases vs matched controls (N = 128 sets)EBV+ HL cases vs matched controls (N = 40 sets)EBV− HL cases vs matched controls (N = 88 sets)EBV+ HL cases vs EBV− HL cases (N = 40 vs 88)*
VCA (IgG ≥ 1:2560)† < 1:2560 2.1 (1.2-3.7) 3.1 (1.1-8.7) 1.7 (0.9-3.5) 1.4 (0.5-3.8) 
EA complex (≥ 1: 40)† < 1:40 1.7 (1.0-2.9) 2.4 (0.9-6.3) 1.4 (0.7-2.8) 1.5 (0.5-4.2) 
EBNA complex (≥ 1:1280)† < 1:1280 1.2 (0.7-2.1) 1.7 (0.6-4.7) 1.0 (0.5-2.0) 1.7 (0.5-6.3) 
    EBNA-1 (≥ 1:1280)† < 1:1280 1.2 (0.6-2.3) 1.4 (0.4-4.6) 1.1 (0.5-2.5) 0.93 (0.2-4.8) 
    EBNA-2 (≥ 1: 80)† < 1:80 1.6 (0.9-2.8) 1.3 (0.5-3.3) 1.8 (0.9-3.5) 0.81 (0.3-2.5) 
    EBNA-1/EBNA-2 ratio (≤ 1.0) > 1.0 1.4 (0.7-2.7) 4.7 (1.6-13.8) 0.4 (0.1-1.3) 14.0 (2.7-72.5) 
AntibodyReferentAll cases vs matched controls (N = 128 sets)EBV+ HL cases vs matched controls (N = 40 sets)EBV− HL cases vs matched controls (N = 88 sets)EBV+ HL cases vs EBV− HL cases (N = 40 vs 88)*
VCA (IgG ≥ 1:2560)† < 1:2560 2.1 (1.2-3.7) 3.1 (1.1-8.7) 1.7 (0.9-3.5) 1.4 (0.5-3.8) 
EA complex (≥ 1: 40)† < 1:40 1.7 (1.0-2.9) 2.4 (0.9-6.3) 1.4 (0.7-2.8) 1.5 (0.5-4.2) 
EBNA complex (≥ 1:1280)† < 1:1280 1.2 (0.7-2.1) 1.7 (0.6-4.7) 1.0 (0.5-2.0) 1.7 (0.5-6.3) 
    EBNA-1 (≥ 1:1280)† < 1:1280 1.2 (0.6-2.3) 1.4 (0.4-4.6) 1.1 (0.5-2.5) 0.93 (0.2-4.8) 
    EBNA-2 (≥ 1: 80)† < 1:80 1.6 (0.9-2.8) 1.3 (0.5-3.3) 1.8 (0.9-3.5) 0.81 (0.3-2.5) 
    EBNA-1/EBNA-2 ratio (≤ 1.0) > 1.0 1.4 (0.7-2.7) 4.7 (1.6-13.8) 0.4 (0.1-1.3) 14.0 (2.7-72.5) 

Data are RR (95% CI).

*

Unconditional logistic regression adjusted for age, sex, race, year of serum collection, and histology.

†

Elevated titer levels.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal